Current and emerging therapeutics for heparin-induced thrombocytopenia

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 1, 2012, Pages 31-37

  Cuker, Adam ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

anticoagulants; heparin induced thrombocytopenia; therapy; treatment

Indexed keywords

ARGATROBAN; DANAPAROID; DESULFATOHIRUDIN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN;

ANTICOAGULANT THERAPY; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; PRIORITY JOURNAL;

EID: 84857024569     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1300949     Document Type: Conference Paper

References (64)

1. Amiral J, Bridey F, Dreyfus M., et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost: 1992; 68 1 95 96
2. Rauova L, Poncz M, McKenzie SE., et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood: 2005; 105 1 131 138 (Pubitemid 40053074)
3. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood: 2005; 106 8 2710 2715 (Pubitemid 41510744)
4. Warkentin TE, Levine MN, Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med: 1995; 332 20 1330 1335
5. Girolami B, Prandoni P, Stefani PM., et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood: 2003; 101 8 2955 2959 (Pubitemid 36857979)
6. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood: 2000; 96 5 1703 1708 (Pubitemid 30661052)
7. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest: 2007; 131 6 1644 1649 (Pubitemid 46981615)
8. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood: 2000; 96 3 846 851 (Pubitemid 30616845)
9. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med: 1996; 101 5 502 507 (Pubitemid 126335970)
10. Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest: 2006; 129 6 1407 1416 (Pubitemid 43894967)
11. Lubenow N, Eichler P, Lietz T, Greinacher A.; Hit Investigators Group. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost: 2005; 3 11 2428 2436 (Pubitemid 41727158)
12. Cuker A. Recent advances in heparin-induced thrombocytopenia. Curr Opin Hematol: 2011; 18 5 315 322
13. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med: 1999; 106 6 629 635 (Pubitemid 29279299)
14. Warkentin TE, Greinacher A, Koster A, Lincoff AM.; American College of Chest Physicians Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest: 2008; 133 340S 380S (Pubitemid 351892970)
15. Cuker A. Heparin-induced thrombocytopenia: present and future. J Thromb Thrombolysis: 2011; 31 3 353 366
16. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med: 2003; 163 15 1849 1856 (Pubitemid 36960936)
17. Lewis BE, Wallis DE, Berkowitz SD., et al. ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation: 2001; 103 14 1838 1843 (Pubitemid 32328395)
18. Cuker A, Arepally G, Crowther MA., et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost: 2010; 8 12 2642 2650
19. Beiderlinden M, Treschan TA, Görlinger K, Peters J. Argatroban anticoagulation in critically ill patients. Ann Pharmacother: 2007; 41 5 749 754 (Pubitemid 46752654)
20. Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost: 2001; 85 3 435 440 (Pubitemid 32233014)
21. Harder S, Graff J, Klinkhardt U., et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin clotting time. Thromb Haemost: 2004; 91 6 1137 1145 (Pubitemid 38821270)
22. Greinacher A, Janssens U, Berg G., et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation: 1999; 100 6 587 593 (Pubitemid 29379746)
23. Greinacher A, Völpel H, Janssens U., et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation: 1999; 99 1 73 80 (Pubitemid 29035960)
24. Tardy B, Lecompte T, Boelhen F., et al. GEHT-HIT Study Group. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood: 2006; 108 5 1492 1496 (Pubitemid 44316113)
25. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood: 2000; 96 7 2373 2378
26. Song X, Huhle G, Wang L, Hoffmann U, Harenberg J. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation: 1999; 100 14 1528 1532 (Pubitemid 29461465)
27. Cardenas GA, Deitcher SR. Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia. Mayo Clin Proc: 2005; 80 4 491 493 (Pubitemid 40471380)
28. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia (HIT). Circulation: 2003; 108 2062 2065 (Pubitemid 37337579)
29. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J: 2001; 142 6 952 959 (Pubitemid 33131801)
30. Lincoff AM, Bittl JA, Harrington RA., et al. REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA: 2003; 289 7 853 863 (Pubitemid 37430344)
31. Dyke CM, Smedira NG, Koster A., et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg: 2006; 131 3 533 539
32. Koster A, Spiess B, Jurmann M., et al. Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the "EVOLUTION OFFo" trial. Anesth Analg: 2006; 103 3 540 544 (Pubitemid 44542900)
33. Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy: 2006; 26 4 452 460
34. Skrupky LP, Smith JR, Deal EN., et al. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia. Pharmacotherapy: 2010; 30 12 1229 1238
35. Kiser TH, Mann AM, Trujillo TC, Hassell KL. Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia. Am J Hematol: 2011; 86 3 267 272
36. Frame JN, Rice L, Bartholomew JR, Whelton A. Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis. Clin Ther: 2010; 32 4 626 636
37. Boyce SW, Bandyk DF, Bartholomew JR, Frame JN, Rice L. A Randomized, Open-Label Pilot Study Comparing Desirudin and Argatroban in Patients with Suspected Heparin-Induced Thrombocytopenia With or Without Thrombosis: PREVENT-HIT Study. Am J Ther: 2010; 18 14 22
38. Chong BH, Gallus AS, Cade JF., et al. Australian HIT Study Group. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost: 2001; 86 5 1170 1175 (Pubitemid 33064563)
39. Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost: 2001; 85 950 957 (Pubitemid 32573742)
40. Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost: 2006; 95 6 967 981 (Pubitemid 43933754)
41. Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost: 2005; 93 5 999 1000 (Pubitemid 40691563)
42. Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost: 2008; 99 1 208 214
43. Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hemost: 2010; 16 6 663 667
44. Pappalardo F, Scandroglio A, Maj G, Zangrillo A, DAngelo A. Treatment of heparin-induced thrombocytopenia after cardiac surgery: preliminary experience with fondaparinux. J Thorac Cardiovasc Surg: 2010; 139 3 790 792
45. Warkentin TE. Fondaparinux: does it cause HIT? Can it treat HIT? Expert Rev Hematol: 2010; 3 5 567 581
46. Motokawa S, Torigoshi T, Maeda Y., et al. IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics. BMC Musculoskelet Disord: 2011; 12 22
47. Warkentin TE, Davidson BL, Buller HR., et al. Prevalence and risk of pre-existing heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest: 2011; 140 2 366 373
48. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med: 2007; 356 25 2653 2655, discussion 2653-2655
49. Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost: 2008; 99 4 779 781 (Pubitemid 351694236)
50. Salem M, Elrefai S, Shrit MA, Warkentin TE. Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. Thromb Haemost: 2010; 104 5 1071 1072
51. Pistulli R, Oberle V, Figulla HR, Yilmaz A, Pfeifer R. Fondaparinux cross-reacts with heparin antibodies in vitro in a patient with fondaparinux-related thrombocytopenia. Blood Coagul Fibrinolysis: 2011; 22 1 76 78
52. Hursting MJ, Soffer J. Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia. Drug Saf: 2009; 32 3 203 218
53. To L, Schillig JM, Desmet BD, Kuriakose P, Szandzik EG, Kalus JS. Impact of a pharmacist-directed anticoagulation service on the quality and safety of heparin-induced thrombocytopenia management. Ann Pharmacother: 2011; 45 2 195 200
54. Cooper T, Taber D, Mazur J. Implementation of a collaborative drug therapy management service for inpatients receiving direct thrombin inhibitors. Am J Health Syst Pharm: 2009; 66 14 1297 1303
55. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood: 2010; 115 1 15 20
56. Hursting MJ, Verme-Gibboney CN. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study. J Cardiovasc Pharmacol: 2008; 52 6 561 566
57. Sachais BS, Rux AH, Hinds JL, Rux JJ. Rational design and characterization of platelet factor 4 antagonists. Paper presented at: Annual Meeting of the American Society of Hematology; December 6,: 2010;; Orlando, FL
58. Reilly MP, Sinha U, Andr P., et al. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood: 2011; 117 7 2241 2246
59. Stolla M, Stefanini L, Andre P., et al. CalDAG-GEFI deficiency protects mice in a novel model of FcRIIA-mediated thrombosis and thrombocytopenia. Blood: 2011; 118 4 1113 1120
60. Nanwa N, Mittmann N, Knowles S., et al. The direct medical costs associated with suspected heparin-induced thrombocytopenia. Pharmacoeconomics: 2011; 29 6 511 520
61. Wilke T, Tesch S, Scholz A, Kohlmann T, Greinacher A. The costs of heparin-induced thrombocytopenia: a patient-based cost of illness analysis. J Thromb Haemost: 2009; 7 5 766 773
62. Baroletti S, Piovella C, Fanikos J, Labreche M, Lin J, Goldhaber SZ. Heparin-induced thrombocytopenia (HIT): clinical and economic outcomes. Thromb Haemost: 2008; 100 6 1130 1135
63. Elalamy I, Le Gal G, Nachit-Ouinekh F., et al. Heparin-induced thrombocytopenia: an estimate of the average cost in the hospital setting in France. Clin Appl Thromb Hemost: 2009; 15 4 428 434
64. Smythe MA, Koerber JM, Fitzgerald M, Mattson JC. The financial impact of heparin-induced thrombocytopenia. Chest: 2008; 134 3 568 573